
tcY-NH2
CAS No. 327177-34-4
tcY-NH2( —— )
Catalog No. M30778 CAS No. 327177-34-4
Selective PAR4 antagonist peptide. Inhibits endostatin release and platelet aggregation induced by thrombin.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NametcY-NH2
-
NoteResearch use only, not for human use.
-
Brief DescriptionSelective PAR4 antagonist peptide. Inhibits endostatin release and platelet aggregation induced by thrombin.
-
DescriptionSelective PAR4 antagonist peptide. Inhibits endostatin release and platelet aggregation induced by thrombin.
-
In VitrotcY-NH2 (0-500 μM) inhibits AYPGKF-NH2 (10 μM)-induced platelet (obtained from male albino Sprague–Dawley rats) aggregation, with an IC50 value of 95 μM.tcY-NH2 potently activates aorta relaxation (RA) and gastric (LM) contraction, with IC50 values of 64 μM (RA) and 1 μM (LM).tcY-NH2 (Tc-YPGKF-NH2, 400 μM, 5 min) prevents endostatin release and platelet aggregation induced by thrombin or by AY-NH2.tcY-NH2 (5 μM, 15 min) decreases infarct size (IS) by 51%, and increases recovery of ventricular function by 26% in an isolated heart model.
-
In VivotcY-NH2 (tail vein injection, 0.6 mg/kg for a single dose) alleviates liver injury in Brain death (BD) rat model, indicated by lower serum ALT/AST levels and better histomorphology.tcY-NH2 (intraperitoneal injection, 0.6 mg/kg for a single dose) increases posttraumatic activation of CD4+ Tregs within the draining lymph nodes in burn injury mice model .tcY-NH2 (intrapleural injection, 40 ng/kg for a single dose) inhibits neutrophil recruitment in experimental inflammation in mice. Animal Model:Brain death (BD) rat model Dosage:0.6 mg/kg for a single doseAdministration:Tail vein injection for a single dose Result:Reduced blood platelet activation and hepatic platelet accumulation.Attenuated the inflammatory response and apoptosis in the livers.Inhibited the activation of NF-κB and MAPK pathways induced by Brain death (BD).Animal Model:Burn injury model of C57BL/6 N mice Dosage:0.6 mg/kg for a single dose Administration:Intraperitoneal injection Result:Increased expression and phosphorylation of PKC-θ in the presence of platelets, without affecting early posttraumatic hemostasis.Animal Model:BALB/c mice Dosage:40 ng/kg for a single dose Administration:Intrapleural injection Result:Abolished the number of rolling and adhering neutrophils on the vessel wall.Inhibited CXCL8- and Cg-induced neutrophil migration into the pleural cavity of mice.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetPAR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number327177-34-4
-
Formula Weight739.87
-
Molecular FormulaC40H49N7O7
-
Purity>98% (HPLC)
-
Solubilitywater:1 mg/mL
-
SMILESNCCCC[C@H](NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)\C=C\C1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hollenberg et al (2004) Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br.J.Pharmacol. 143 443 PMID:
molnova catalog



related products
-
FSLLRY-NH2
Selective PAR2 peptide antagonist. Reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice. Blocks ERK activation and collagen production in isolated cardiac fibroblasts. Also reduces symptoms in a mouse model of dermatophyte-associated itch.
-
TFLLR-NH2(TFA)
TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM. EC50: 1.9 μM (PAR1)
-
BMS-986120
BMS-986120 (BMS986120)?is a potent, selective, orally bioavailable, and reversible PAR4 antagonist with Kd of 0.098 nM for human PAR4.